Abstract
Background
Evaluating antibody titers for Sarcocystis neurona for the diagnosis of equine protozoal myeloencephalitis from serum samples is a common practice. However, ensuring timely and proper refrigeration is not always possible.
Objectives
To evaluate immunofluorescent antibody (IFA) titers for S. neurona from serum samples stored at room temperature and 4°C.
Samples
Twenty‐two serum samples.
Methods
Prospective longitudinal study. Two serum aliquots of 1 mL each were stored at room temperature (20‐23.3°C) and 4°C. The unrefrigerated aliquot was immediately tested for IFA titers. Both aliquots were retested on Days 5 and 10 after collection. A paired t test was used to compare IFA titers at different time points.
Results
There was no significant difference between IFA titers from baseline with those stored at room temperature at Days 5 (P = .741, 95% CI [−56.83, 78.65]), 10 (P = .677, 95% CI [−50.01, 75.46]), and between 5 and 10 days (P = 0.949, 95% CI [−57.50, 61.14]). There was no significant difference from baseline with those stored at 4°C for Days 5 (P = .964, 95% CI [−81.81, 85.45]), 10 (P = 0.573, 95% CI [−109.4, 62.15]), and between 5 and 10 days (P = .5, 95% CI [−102.6, 51.67]). There was no statistical difference between samples stored at room temperature and 4°C (P = .688, CI [−55.51, 37.33]) on Days 5 and 10 (P = .104, CI [−80.8, 8.07]).
Conclusions and Clinical Importance
Immunofluorescent antibody test titers for S. neurona are stable for up to 10 days at room temperature and 4°C.
Keywords: ambient temperature, antibodies, cold, protein, protozoa, stability
Abbreviations
- CSF
cerebrospinal fluid
- CNS
central nervous system
- EPM
equine protozoal myeloencephalitis
- IFA
immunofluorescent antibody
- IFAT
immunofluorescent antibody test
1. INTRODUCTION
Equine protozoal myeloencephalitis (EPM) is a progressively debilitating neurological disease reported in horses in the Americas. 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 It is mainly associated with the protozoan Sarcocystis neurona although Neospora hughesi and Toxoplasma gondii have also been proposed as etiologic agents associated with disease because of evidence of intrathecal antibody production for both pathogens. 10 , 11 , 12 , 13 , 14 Clinical signs depend on the neuroanatomic location within the central nervous system (CNS), and can vary from acute to subacute to chronic, focal or multifocal neurological signs involving the brain, spinal cord, or both. 10 The definitive diagnosis of EPM requires confirmation of protozoal infection in the CNS through postmortem examination. 1 However, antemortem diagnosis can be suspected by performing a complete neurological examination to confirm signs compatible with the disease, ruling out other possible neurological diseases, and determining the production of intrathecal antibodies against the parasite by immunological diagnostic techniques such as immunofluorescent antibody test (IFAT), and S. neurona surface antigen (SnSAG) immunosorbent assays (ELISA). 10 , 11 , 15 , 16
Considering the risks and costs associated with performing a cerebrospinal fluid (CSF) collection, evaluating serum antibody titers for S. neurona in many cases is the first step in the investigation of EPM as a possible clinical diagnosis. Although the presence of antibodies in serum does not confirm the clinical disease, 10 , 17 , 18 their determination is used to estimate the probability of having EPM, 11 , 16 rule out infection, or conduct epidemiological studies to determine seroprevalence. 4 , 18 , 19 , 20 A common practice among veterinarians when transporting serum samples for diagnosis is to refrigerate them; however, in some cases, because of distance or challenges related to the shipment of samples, ensuring timely and proper refrigeration might not be possible in every case. Additionally, veterinarians from countries without access to specialized laboratories with validated diagnostic tests send serum samples to the United States of America for processing. This might result in delay of processing and analyzing samples soon after collection, often taking several days. Preanalytical considerations such as temperature and time of storage have been described in humans to optimize immunological test results. 21 To our knowledge, there are no studies evaluating the effect of refrigeration and room temperature on serum antibody titers for S. neurona in horses. Therefore, the objective of the study was to evaluate the effect of refrigeration and room temperature as well as time of storage on immunofluorescent antibody (IFA) titers for S. neurona in serum. We hypothesized that IFA from serum samples stored at room temperature, provided temperate weather, would be stable for at least 5 days.
2. MATERIALS AND METHODS
This is a prospective longitudinal study comparing IFA titers from serum samples stored at room temperature (20‐23.3°C [68‐74°F]) and under refrigeration at 4°C (39.2°F) at 3 different time points: Day 1 = day of collection (baseline), Day 5, and Day 10 after collection.
2.1. Serum samples
Serum samples from 22 horses from our research herd, previously identified as having IFA titers for S. neurona were used for the study. Ten milliliters of whole blood was collected in red top tubes with no anticoagulant by venipuncture of the jugular vein. Once clotted, the samples were centrifuged at 1000g for 10 minutes and serum was collected. Two aliquots of 1 mL each were separated and stored, 1 at room temperature and the other under refrigeration at 4°C. The unrefrigerated aliquot was immediately tested for antibodies to S. neurona using IFAT as previously described. 15 Both aliquots were processed again for the detection of IFA on Days 5 and 10 after collection. Serum dilutions started at 1 : 40 and the end‐point titer was the last serum dilution showing distinct, whole parasite fluorescence. Although it has been reported that a difference in IFA titers of 1 to 2 dilutions (increased or decreased) is not considered significantly different based on validation studies, 11 , 22 , 23 comparison of baseline samples to Days 5 and 10 in this study was based on IFA end‐point titers. This approach is consistent with clinicians being able to calculate serum to CSF IFAT ratios. 16 , 24 This is important because the antemortem clinical diagnosis of EPM is supported by a low IFAT ratio ≤64. 24 The study was approved by the University of California Davis Institutional Animal Care and Use Committee (IACUC, protocol #23833).
2.1.1. Sample size calculation
To determine the required sample size for our study, we conducted a sample size analysis based on the expected effect size and the desired 80% statistical power. Assuming an effect size (Cohen's d) of 0.8, the analysis indicated that a minimum of 14 samples was necessary to achieve this power at a significance level of P = .05. This number is smaller than the current sample size of 22 samples.
2.2. Statistical analysis
For statistical analysis, SAS software version 9.4 (SAS Institute, Cary, NC) was used. The normality of serum titers was assessed with the Shapiro‐Wilk test. Given the normality of the sample, a paired t test was employed for comparing antibody titers across different time points, assuming equal variances between groups. The dependent or outcome variable was the IFAT titer. The independent variables were time point (Day 0, Day 5, Day 10) and storage condition (room temperature or 4°C). The outcome comparison was the difference in IFAT titers over time and under different storage conditions.
3. RESULTS
The dataset comprised serum samples from 22 horses (14 geldings, 8 mares) of mostly Thoroughbred breed (N = 11), with a mean age of 12.5 years old. Upon analyzing the data, no statistically significant differences (P > .05) were observed in IFA titers from baseline (Day 1) to the subsequent titers on Days 5 and 10 at room temperature and under refrigeration at 4°C. Furthermore, there were no differences in IFA titers at each time point between samples stored at room temperature and under refrigeration at 4°C.
3.1. Serum IFA titers at room temperature over time
Comparing serum IFA titers for S. neurona at baseline with those from samples stored at room temperature for 5 days showed no statistically significant difference (P = .741, 95% CI [−56.83, 78.65]) as determined by the paired t test. Comparing serum IFA titers for S. neurona at baseline with those from samples stored at room temperature for 10 days showed no statistically significant difference (P = .677, 95% CI [−50.01, 75.46]). Comparing serum IFA titers for S. neurona at room temperature between Days 5 and 10, there was no statistical difference (P = 0.949, 95% CI [−57.50, 61.14]).
3.2. Serum IFA titers under refrigeration at 4°C
Comparing serum IFA titers for S. neurona at baseline with those from samples stored at 4°C for 5 days showed no statistically significant difference (P = .964, 95% CI [−81.81, 85.45]). Comparing serum IFA titers for S. neurona at baseline with those from samples stored at 4°C for 10 days showed no statistically significant difference (P = 0.573, 95% CI [−109.4, 62.15]). Comparing serum IFA titers for S. neurona at 4°C between Days 5 and 10, there was no statistical difference (P = .5, 95% CI [−102.6, 51.67]).
3.3. Serum IFA titers at room temperature and under refrigeration at 4°C
There was no statistical difference in IFA titers for S. neurona between samples stored at room temperature and under refrigeration (P = .688, CI [−55.51, 37.33]) on Day 5. There was no statistical difference in IFA titers for S. neurona between samples stored at room temperature and under refrigeration (P = .104, CI [−80.8, 8.07]) on Day 10.
4. DISCUSSION
The present study demonstrated that immunofluorescent antibodies for S. neurona in serum remain stable for at least 10 days regardless of whether the serum is refrigerated at 4°C or kept at room temperature.
Preanalytical factors include all the steps before the performance of the diagnostic test in the laboratory and have been classified into 2 general categories: (1) technical effects because of sampling technique and management before analysis, including stability of the specimen during storage and shipping to the laboratory, and (2) biological factors inherent to the animal sampled. 25 , 26 Despite the importance of the preanalytical phase, there are a few studies evaluating preanalytical conditions in human and veterinary medicine, 27 including those that might affect serum antibody measurements in horses.
Previous studies conducted in horses and humans evaluating the effect of room temperature and refrigeration over time on different antibodies have reported stability of immunoglobulins up to 72 hours and 6 days at room temperature and 4°C, respectively. 21 , 28 Another study evaluated the effects of delayed centrifugation, temperature, and storage stability of specific IgE antibodies in serum and found that serum IgE is stable at room temperature for 48 hours before centrifugation and 10 days at 5°C after centrifugation. 29
Limitations of the study included that IFA for other etiologic pathogens associated with EPM such N. hughesi and T. gondii, as well as CSF antibodies, which are indispensable to confirm intrathecal production of antibodies, were not evaluated because of availability. Another limitation is that the samples were centrifuged immediately after coagulation, which is not commonly done by field veterinarians when taking samples and needs investigation. Also, this study was conducted with room environmental temperatures within the range of 20 to 23.3°C (68‐74°F), and the effects on the stability of antibodies from serum samples under other environmental temperatures were not evaluated here. Therefore, it is uncertain if similar results might have been observed.
In conclusion, our study indicates that serum IFA for S. neurona is stable for up to 10 days at both, room temperature or stored at 4°C. This suggests that results obtained from unrefrigerated samples on which the cold chain cannot be guaranteed or those that are not tested soon after collection are reliable. However, refrigeration might still be the best practice if major fluctuations in environmental temperature from transportation to analysis cannot be predicted.
CONFLICT OF INTEREST DECLARATION
Authors declare no conflict of interest.
OFF‐LABEL ANTIMICROBIAL DECLARATION
Authors declare no off‐label use of antimicrobials.
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION
Approved by the University of California Davis IACUC, protocol #23833.
HUMAN ETHICS APPROVAL DECLARATION
Authors declare human ethics approval was not needed for this study.
ACKNOWLEDGMENT
Funding provided by The Seed Grants for International Activities Program, sponsored by Global Affairs at UCD #PD1001 (Aleman), and from gifts from anonymous donors towards the Equine and Comparative Neurology Research Group at UCD #V435AM2 (Aleman).
Valderrama‐Martinez C, Packham A, Zheng S, Smith W, Plancarte M, Aleman M. Effect of refrigeration, room temperature, and processing time on serum immunofluorescent antibody titers for Sarcocystis neurona . J Vet Intern Med. 2025;39(1):e17282. doi: 10.1111/jvim.17282
REFERENCES
- 1. Dubey JP. Invited review: Sarcocystis neurona, Neospora spp. and Toxoplasma gondii infections in horses and equine protozoal myeloencephalitis (EPM): five decades of personal experience, perspectives, and update. Parasitology. 2022;149:1‐44. [DOI] [PubMed] [Google Scholar]
- 2. Dubey JP, Howe DK, Furr M, et al. An update on Sarcocystis neurona infections in animals and equine protozoal myeloencephalitis (EPM). Vet Parasitol. 2015;209:1‐42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Fayer R, Mayhew IG, Baird JD, et al. Epidemiology of equine protozoal myeloencephalitis in North America based on histologically confirmed cases. A report. J Vet Intern Med. 1990;4:54‐57. [DOI] [PubMed] [Google Scholar]
- 4. More G, Vissani A, Pardini L, et al. Seroprevalence of Sarcocystis neurona and its association with neurologic disorders in Argentinean horses. J Equine Vet Sci. 2014;34:1051‐1054. [Google Scholar]
- 5. Llano HAB, Soares RM, Acevedo‐Gutierrez LY, et al. Seroepidemiology of Sarcocystis neurona and Neospora spp. in horses, donkeys, and mules from Colombia. Acta Trop. 2021;220:105970. [DOI] [PubMed] [Google Scholar]
- 6. Wobeser BK, Godson DL, Rejmanek D, Dowling P. Equine protozoal myeloencephalitis caused by Neospora hughesi in an adult horse in Saskatchewan. Can Vet J. 2009;50:851‐853. [PMC free article] [PubMed] [Google Scholar]
- 7. Alvarado‐Esquivel C, Howe DK, Yeargan MR, Alvarado‐Esquivel D, Alfredo Zamarripa‐Barboza J, Dubey JP. Seroepidemiology of Sarcocystis neurona and Neospora hughesi infections in domestic donkeys (Equus asinus) in Durango, Mexico. Parasite. 2017;24:27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Yeargan MR, Alvarado‐Esquivel C, Dubey JP, Howe DK. Prevalence of antibodies to Sarcocystis neurona and Neospora hughesi in horses from Mexico. Parasite. 2013;20:29. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Brown CM, Morrow JK, Carleton CL, et al. Persistence of serum antibodies to Sarcocystis neurona in horses moved from North America to India. J Vet Intern Med. 2006;20:994‐997. [DOI] [PubMed] [Google Scholar]
- 10. Reed SM, Furr M, Howe DK, et al. Equine protozoal myeloencephalitis: an updated consensus statement with a focus on parasite biology, diagnosis, treatment, and prevention. J Vet Intern Med. 2016;30:491‐502. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Packham AE, Conrad PA, Wilson WD, et al. Qualitative evaluation of selective tests for detection of Neospora hughesi antibodies in serum and cerebrospinal fluid of experimentally infected horses. J Parasitol. 2002;88:1239‐1246. [DOI] [PubMed] [Google Scholar]
- 12. Renier AC, Morrow JK, Graves AJ, et al. Diagnosis of equine protozoal myeloencephalitis using indirect fluorescent antibody testing and enzyme‐linked immunosorbent assay titer ratios for Sarcocystis neurona and Neospora hughesi . J Equine Vet Sci. 2016;36:49‐51. [Google Scholar]
- 13. Bernardino PN, Pusterla N, Conrad PA, et al. Evidence of intrathecally‐derived antibodies against Toxoplasma gondii in horses suspected of neurological disease consistent with equine protozoal myeloencephalitis. Vet Parasitol. 2023;318(109919):109911‐109915. [DOI] [PubMed] [Google Scholar]
- 14. James KE, Smith WA, Packham AE, Conrad PA, Pusterla N. Toxoplasma gondii seroprevalence and association with equine protozoal myeloencephalitis: a case‐control study of Californian horses. Vet J. 2017;224:38‐43. [DOI] [PubMed] [Google Scholar]
- 15. Johnson AL, Morrow JK, Sweeney RW. Indirect fluorescent antibody test and surface antigen ELISAs for antemortem diagnosis of equine protozoal myeloencephalitis. J Vet Intern Med. 2013;27:596‐599. [DOI] [PubMed] [Google Scholar]
- 16. Pandit PS, Smith WA, Finno CJ, et al. A fresh look at the SarcoFluor antibody test for the detection of specific antibodies to Sarcocystis neurona for the diagnosis of equine protozoal myeloencephalitis. Vet Parasitol. 2024;330:110219. [DOI] [PubMed] [Google Scholar]
- 17. Pusterla N, Packham A, Wilson WD, et al. Short communication: evaluation of the kinetics of antibodies against Sarcocystis neurona in serum from seropositive healthy horses without neurological deficits treated with ponazuril paste. Vet Rec. 2013;173:249. [DOI] [PubMed] [Google Scholar]
- 18. Pusterla N, Tamez‐Trevino E, White A, et al. Comparison of prevalence factors in horses with and without seropositivity to Neospora hughesi and/or Sarcocystis neurona . Vet J. 2014;200:332‐334. [DOI] [PubMed] [Google Scholar]
- 19. Gomes FA, Jansen AM, Machado RZ, et al. Serological evidence of arboviruses and coccidia infecting horses in the Amazonian region of Brazil. PLoS One. 2019;14:e0225895. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. James KE, Smith WA, Conrad PA, et al. Seroprevalences of anti‐Sarcocystis neurona and anti‐Neospora hughesi antibodies among healthy equids in the United States. J Am Vet Med Assoc. 2017;250:1291‐1301. [DOI] [PubMed] [Google Scholar]
- 21. Hodgkinson VS, Egger S, Betsou F, et al. Preanalytical stability of antibodies to pathogenic antigens. Cancer Epidemiol Biomarkers Prev. 2017;26:1337‐1344. [DOI] [PubMed] [Google Scholar]
- 22. Miller MA, Gardner IA, Packham A, et al. Evaluation of an indirect fluorescent antibody test (IFAT) for demonstration of antibodies to Toxoplasma gondii in the sea otter (Enhydra lutris). J Parasitol. 2002;88:594‐599. [DOI] [PubMed] [Google Scholar]
- 23. Miller MA, Crosbie PR, Sverlow KW, et al. Isolation and characterization of Sarcocystis from brain tissue of a free living southern sea otter (Enhydra lutris nereis) with fatal meningoencephalitis. Parasitol Res. 2001;87:252‐257. [DOI] [PubMed] [Google Scholar]
- 24. Duarte PC, Daft BM, Conrad PA, et al. Evaluation and comparison of an indirect fluorescent antibody test for detection of antibodies to Sarcocystis neurona, using serum and cerebrospinal fluid of naturally and experimentally infected, and vaccinated horses. J Parasitol. 2004;90:379‐386. [DOI] [PubMed] [Google Scholar]
- 25. Braun JP, Bourgès‐Abella N, Geffré A, Concordet D, Trumel C. The preanalytic phase in veterinary clinical pathology. Vet Clin Pathol. 2015;44:8‐25. [DOI] [PubMed] [Google Scholar]
- 26. Rossi G, Richardson A, Jamaludin H, Secombe C. Preanalytical variables affecting the measurement of serum paraoxonase‐1 activity in horses. J Vet Diagn Invest. 2021;33:59‐66. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Gunn‐Christie RG, Flatland B, Friedrichs KR, et al. ASVCP quality assurance guidelines: control of preanalytical, analytical, and postanalytical factors for urinalysis, cytology, and clinical chemistry in veterinary laboratories. Vet Clin Pathol. 2012;41:18‐26. [DOI] [PubMed] [Google Scholar]
- 28. Frohlich M, Knights K, Springer NL. Determination of optimal storage time and temperature for the detection of red blood cell and platelet surface‐associated immunoglobulin by flow cytometry in healthy horses. Vet Immunol Immunopathol. 2023;263:110643. [DOI] [PubMed] [Google Scholar]
- 29. Østergaard M, Sandfeld‐Paulsen B. Preanalytical temperature and storage stability of specific IgE antibodies in serum. Scand J Clin Lab Invest. 2023;83:160‐165. [DOI] [PubMed] [Google Scholar]
